Epidermal growth factor receptor (EGFR), a membrane tyrosine kinase receptor expressed in the kidney, is activated after renal damage, leading to cell proliferation and kidney fibrosis, and preclinical studies have provided evidence for its potential as a therapeutic target in polycystic kidney disease (Gattone et al., 1995; Veizis and Cotton, 2005; Ryan et al., 2010). This evidence concerns the gene EGFR and polycystic kidney disease.